KBLB Kraig Biocraft Laboratories Inc.

Kraig Biocraft Laboratories Announces Early Start to Production Season with Successful Small Batch Delivery of Spider Silk

Kraig Biocraft Laboratories Announces Early Start to Production Season with Successful Small Batch Delivery of Spider Silk

ANN ARBOR, Mich., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, today announces the early start to the production season with the successful manufacture and delivery of the most recent batch of recombinant spider silk. Silk from this production cycle was processed into finished reeled raw silk and happily received on site by the Company’s Senior management this week.

The delivery of this silk further reinforces the Company’s planned production model. With this successful effort, the Company is now accelerating its plans for the upcoming 2024 production season and beyond.

“I am very excited to have produced this small batch ahead of our upcoming field trials scheduled for this spring. This early production bodes very well for the pending trials, and indicates, to me, that we are well on track to meet our spider silk production targets for 2024,” said CEO and Founder Kim Thompson.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (), a reporting biotechnology company, is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward-Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward-looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

A photo accompanying this announcement is available at



EN
14/12/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kraig Biocraft Laboratories Inc.

 PRESS RELEASE

From Lab Fiber to Luxury Fabric: Kraig Biocraft Laboratories Targets A...

From Lab Fiber to Luxury Fabric: Kraig Biocraft Laboratories Targets Apparel First with Engineered Spider Silk DENVER, April 02, 2026 (GLOBE NEWSWIRE) -- () -- Kraig Biocraft Laboratories (OTCQB: KBLB) is advancing a transgenic silkworm platform designed to produce recombinant spider silk at commercial scale, positioning the company at the intersection of genetic engineering, materials science, and textile manufacturing. Spider silk has long been studied for its combination of strength, elasticity, and low weight. The challenge has been producing it economically at scale. Kraig’s approac...

 PRESS RELEASE

Kraig Biocraft Laboratories Deploys Over 700,000 BAM-1 Alpha Productio...

Kraig Biocraft Laboratories Deploys Over 700,000 BAM-1 Alpha Production Hybrids, Achieving Key Milestone in its Aggressive Scale-Up Plan ANN ARBOR, Mich., March 30, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced the successful deployment of more than 700,000 BAM-1 Alpha production hybrids of its previously reported 1,000,000 egg inventory. These silkworms are now in active production. This achievement underscores the Company's continued execution of its previou...

 PRESS RELEASE

Kraig Biocraft Laboratories Increases R&D Capacity, as Project Atlas B...

Kraig Biocraft Laboratories Increases R&D Capacity, as Project Atlas Breakthroughs Creating New Spider Silk Transgenics ANN ARBOR, Mich., March 23, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a significant expansion of its research and development capacity designed to keep pace with rapid progress of its advanced materials initiative, Project Atlas. The Company has expanded its laboratory capabilities, onboarding new scientific personnel and the deploymen...

 PRESS RELEASE

Engineered Silkworms Spin Spider Silk as Biotech Firm Targets Commerci...

Engineered Silkworms Spin Spider Silk as Biotech Firm Targets Commercial Scale DENVER, March 18, 2026 (GLOBE NEWSWIRE) --  -- A biotechnology company developing genetically engineered silkworms says it’s moving toward commercial production of spider silk, a material long sought by researchers for its unusual combination of strength and elasticity. Kraig Biocraft Laboratories (OTCQB: KBLB) deployed one million genetically engineered silkworm eggs across multiple production facilities in Vietnam as part of a Spring scale-up effort that could eventually produce around 10 metric tons of reco...

 PRESS RELEASE

24/7 Market News: Kraig Labs the Bootstrapped Unicorn in the Making

24/7 Market News: Kraig Labs the Bootstrapped Unicorn in the Making DENVER, March 11, 2026 (GLOBE NEWSWIRE) -- -- In technology and biotechnology, “unicorn” status is typically reserved for private companies valued at $1 billion or more; often backed by major venture rounds, institutional syndicates, and aggressive capital deployment strategies. But what happens when a company advances a platform with billion-dollar potential without the backing of Silicon Valley mega-funding? That question is increasingly being asked about Kraig Biocraft Laboratories (OTCQB: KBLB). More than a decade ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch